Dysfunction of high-density lipoprotein and its apolipoproteins: New mechanisms underlying cardiometablic risk in the population at large

Turk Kardiyoloji Dernegi Arsivi

Volumn 40, Issue 4, 2012, Pages 368-385

  Onat, Altan ^a   Can, Günay ^a   Yüksel, Hüsniye ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apolipoproteins; Cardiometabolic risk; Cholesterol; Coronary disease; Diabetes mellitus; High density lipoprotein; Hypertriglyceridemias; LDL blood; Metabolic syndrome; Smoking

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN D; APOLIPOPROTEIN E; APOLIPOPROTEIN F; APOLIPOPROTEIN G; APOLIPOPROTEIN I; BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE; PHOSPHOLIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; BODY HEIGHT; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COMPLEX FORMATION; DIABETIC PATIENT; ENDOTHELIAL DYSFUNCTION; FAMILY HISTORY; GLYCATION; HUMAN; HYPERURICEMIA; INCOME; ISCHEMIC HEART DISEASE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATION; PARTICLE SIZE; PREHYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SMOKING; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASES; METABOLIC SYNDROME X; METABOLISM;

APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, HDL; METABOLIC SYNDROME X; RISK FACTORS;

EID: 84882745217     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: 10.5543/tkda.2012.55490     Document Type: Review

References (96)

1. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904. (Pubitemid 37430461)
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
3. Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005;293:1868-74. (Pubitemid 40548183)
4. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:85-151.
5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8. (Pubitemid 38133916)
6. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61.
7. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008;5:319-35.
8. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46-57. (Pubitemid 41007806)
9. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-67.
10. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56. (Pubitemid 46348533)
11. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL - an evolving field. Nat Clin Pract Endocrinol Metab 2006;2:504-11. (Pubitemid 44353291)
12. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-6. (Pubitemid 37498976)
13. Vaisar T, Mayer P, Nilsson E, Zhao XQ, Knopp R, Prazen BJ. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 2010;411:972-9.
14. Calvo C, Ponsin G, Berthezene F. Characterization of the non enzymatic glycation of high density lipoprotein in diabetic patients. Diabete Metab 1988;14:264-9.
15. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010;30:151-5.
16. Kontush A, Chapman MJ. Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 2008;8:51-9. (Pubitemid 351384876)
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
18. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42. (Pubitemid 351186873)
19. Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 2006;187:191-7. (Pubitemid 43817014)
20. van Acker BA, Botma GJ, Zwinderman AH, Kuivenhoven JA, Dallinga-Thie GM, Sijbrands EJ, et al REGRESS Study Group. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis 2008;200:161-7.
21. Briel M, Ferreira-Gonzales I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.
22. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9. (Pubitemid 44205015)
23. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008;10:213.
24. Tohidi M, Hatami M, Hadaegh F, Safarkhani M, Harati H, Azizi F. Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8.6 years follow-up of a population based cohort study. Lipids Health Dis 2010;9:6.
25. Henderson RJ, Wasan KM, Leon CG. Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma. Lipids Health Dis 2009;8:27.
26. Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008;57:2794-800.
27. Zhang L, Qiao Q, Laatikainen T, Söderberg S, Jousilahti P, Onat A, et al. The impact of dyslipidaemia on incidence of coronary heart disease in Finns and Swedes with different categories of glucose tolerance. Diabetes Res Clin Pract 2011;91:406-12.
28. Onat A, Can G, Ayhan E, Kaya Z, Hergenç G. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. Metabolism 2009;58:1393-9.
29. Onat A, Hergenç G, Bulur S, Uǧur M, Küçü kdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks, Int J Cardiol 2010;142:72-9.
30. Onat A, Hergenç G. Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011;60:499-512.
31. Onat A, Can G, Hergenç G, Uǧur M, Yüksel H. Coronary disease risk prediction algorithm warranting incorporation of C-reactive protein in Turkish adults, manifesting sex difference. Nutr Metab Cardiovasc Dis 2012;22:643-50.
32. Onat A, Can G, Yüksel H, Ayhan E, Dogan Y, Hergenç G. An algorithm to predict risk of type 2 diabetes in Turkish adults: contribution of C-reactive protein. J Endocrinol Invest 2011;34:580-6.
33. Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M, et al. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 2008;397:42-7.
34. Jang W, Jeoung NH, Cho KH. Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state. Mol Cells 2011;31:461-70.
35. Teoh CL, Griffin MD, Hewlett GJ. Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell 2011;2:116-27.
36. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
37. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.
38. Zechner R, Desoye G, Schweditsch MO, Pfeiffer KP, Kostner GM. Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum. Metabolism 1986;35:333-6. (Pubitemid 16079525)
39. Bersot TP, Innerarity TL, Pitas RE, Rall SC Jr, Weisgraber KH, Mahley RW. Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages. J Clin Invest 1986;77:622-30. (Pubitemid 16037665)
40. Rosseneu M, Labeur C, Vinaimont R, de Slypere JP, Matthys E. Plasma Lp(a) patterns after triglyceride infusion. Atherosclerosis Rev 1991;22:137-43.
41. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010;362:906-16.
42. Onat A, Yazici M, Can G, Kaya Z, Bulur S, Hergenç G. Predictive value of prehypertension for metabolic syndrome, diabetes, and coronary heart disease among Turks. Am J Hypertens 2008;21:890-5.
43. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SR Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and non-lipid factors. Circulation 1990;81:470-6. (Pubitemid 20055954)
44. Onat A, Hergenç G, Ayhan E, Uǧur M, Kaya H, Tuncer M, et al. Scrum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. Diabet Med 2009;26:981-8.
45. Juntti-Berggren L, Refai E, Appelskog I, Andersson M, Imreh G, Dekki N, et al. Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. Proc Natl Acad Sci U S A 2004;101:10090-4. (Pubitemid 38891199)
46. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006;114:681-7. (Pubitemid 44252310)
47. Gucy LT, Pullinger CR, Ishida BY, O'Connor PM, Zellner C, Francone OL, et al. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol 2011;108:360-6.
48. Sharp DS, Burchfiel CM, Rodriguez BL, Sharrett AR, Sorlie PD, Marcovina SM. Apolipoprotein A-1 predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japanese-Americans. Int J Clin Lab Res 2000;30:39-48. (Pubitemid 30427948)
49. Onat A, Can G, Ömek E, Çiçek G, Ayhan E, Doǧan Y. Serum γ-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring) 2012;20:842-8.
50. Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 2007;4:e270.
51. Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 2011;48:498-515.
52. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver C, Baudet A, Sly W, Valle S, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill Inc; 2001. p. 2705-960.
53. Onat A, Kömürcü-Bayrak E, Can G, Küçü kdurmaz Z, Hergenç G, Erginel-Unaltuna N. Apolipoprotein A-I positively associated with diabetes in women independently of apolipoprotein E genotype and apolipoprotein B levels. Nutrition 2010;26:975-80.
54. Onat A, Can G, Rezvani R, Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 2011;412:1171-9.
55. Onat A, Hergenç G, Can G, Kaya Z, Yüksel H. Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population. Metabolism 2010;59:628-34.
56. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L; NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138:24-32. (Pubitemid 36232091)
57. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. N Engl J Med 1995;333:677-85.
58. Flegal KM, Troiano RP, Pamuk ER, Kuczmarski RJ, Campbell SM. The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med 1995;333:1165-70.
59. Visscher TL, Rissanen A, Seidell JC, Heliövaara M, Knekt P, Reunanen A, et al. Obesity and unhealthy life-years in adult Finns: an empirical approach. Arch Intern Med 2004;164:1413-20. (Pubitemid 38937852)
60. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
61. Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003;24:1365-72. (Pubitemid 36917708)
62. Onat A, Can G, Hergenç G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabolism 2008;57:207-14.
63. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007;191:182-90. (Pubitemid 46237629)
64. Onat A, Uǧur M, Hergenç G, Can G, Ordu S, Dursunoǧlu D. Lifestyle and metabolic determinants of incident hypertension, with special reference to cigarette smoking: a longitudinal population-based study Am J Hypertens 2009;22:156-62.
65. Onat A, Hergenç G, Can G, Karabulut A. Serum asymmetric dimethylarginine levels among Turks: association with metabolic syndrome in women and tendency to decrease in smokers. Turk Kardiyol Dern Ars 2008;36:7-13.
66. Onat A, Hergenç G, Uyarel H, Ozhan H, Esen AM, Karabulut A, et al. Association between mild renal dysfunction and insulin resistance or metabolic syndrome in a random nondiabetic population sample. Kidney Blood Press Res 2007;30:88-96. (Pubitemid 46674913)
67. Onat A, Ayhan E, Hergenç G, Can G, Barlan MM. Smoking inhibits visceral fat accumulation in Turkish women: relation of visceral fat and body fat mass to atherogenic dyslipidemia, inflammatory markers, insulin resistance, and blood pressure. Metabolism 2009;58:963-70.
68. Onat A, Can G, Ciçck G, Doǧan Y, Kaya H, Gümrükçüoǧlu HA, et al. Diverging sex-specific long-term effects of cigarette smoking on fasting insulin and glucose levels in nondiabetic people. Clin Biochem 2012;45:37-42.
69. Onat A, Ozhan H, Esen AM, Albayrak S, Karabulut A, Can G, et al. Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women-without associated overall health benefit. Atherosclerosis 2007;193:380-8. (Pubitemid 47058101)
70. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willelt WC, Rosner B, et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health 1993;83(2):211-4. (Pubitemid 23046478)
71. Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 2010;69:61-64.
72. Onat A, Direskeneli H. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 2012;18:1465-77.
73. Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 2005;201:1113-23. (Pubitemid 40524679)
74. Wong ND, Pio J, Valencia R, Thakal G. Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III. Prev Cardiol 2001;4:109-114 (Pubitemid 32613801)
75. Onat A, Can G, Ciçek G, Ayhan E, Doǧan Y, Kaya H. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults. Acta Diabetol 2011 Jul 16. [ePiib]
76. Onat A, Hergenç G, Can G, Uǧur M, Nartop F. Dual activity of serum lipoprotein-associated phospholipase A(2) yielding positive and inverse associations with cardiometabolic risk. Clin Chem Lab Med 2011;49:1349-57.
77. O'Keefe JH, Gheewala NM, O'Keefe JO. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008;51:249-55.
78. American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96.
79. Mitrou PN, Kipnis V, Thiébaut AC, Reedy J, Subar AF, Wirfält E, et al. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med 2007;167:2461-8. (Pubitemid 350254905)
80. Arora SK, McFarlane SI. The case for low carbohydrate diets in diabetes management. Nutr Metab (Lond) 2005;2:16.
81. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999;319:1523-8.
82. Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: a systematic review of the literature. Obes Rev 2006;7:183-200.
83. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361:477-85. (Pubitemid 36173713)
84. Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA; Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia 2009;52:50-9.
85. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008;51:1512-24. (Pubitemid 351470037)
86. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-61.
87. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010;121:110-22.
88. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. (Pubitemid 17208898)
89. Gleim G, Ballantyne CM, Liu N, Thompson-Bell S, McCrary Sisk C, Pasternak RC, et al. Efficacy and safety profile of coadministered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol 2009;16:90-7.
90. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
91. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45. (Pubitemid 17147964)
92. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.
93. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Grouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
94. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84.
95. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-72.
96. Bestermann WH Jr. The ADMA-Metformin Hypothesis: Linking the Cardiovascular Consequences of the Metabolic